UBS raised the firm’s price target on Amgen (AMGN) to $400 from $390 and keeps a Buy rating on the shares. The firm adjusted targets in the pharmaceuticals and biotechnology group as part of a Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s FORWARD II Gout Study: What a Less Frequent Krystexxa Schedule Could Mean for Investors
- Amgen price target raised to $326 from $309 at Morgan Stanley
- Amgen price target raised to $351 from $347 at Guggenheim
- Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating
- Amgen price target raised to $325 from $319 at Truist